Targeting the epidermal growth factor receptor in non-small-cell lung cancer: Who, which, when, and how?

Current Oncology Reports

Volumn 9, Issue 4, 2007, Pages 255-264

  Juergens, Rosalyn ^a   Brahmer, Julie ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; IRINOTECAN; K RAS PROTEIN; MONOCLONAL ANTIBODY; NAVELBINE; PACLITAXEL; PLACEBO; PLATINUM DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB;

BREAST CANCER; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CARCINOMA; COMBINATION CHEMOTHERAPY; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG INDICATION; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG METABOLISM; DRUG RESPONSE; DRUG TARGETING; ETHNICITY; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; GENE OVEREXPRESSION; HEAD AND NECK CANCER; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; LUNG ALVEOLUS CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MAXIMUM TOLERATED DOSE; MEDICAL DECISION MAKING; METASTASIS; MONOTHERAPY; ONCOGENE K RAS; PANCREAS CANCER; PATIENT SELECTION; REVIEW; SEX DIFFERENCE; SIGNAL TRANSDUCTION; SMOKING HABIT;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 34447272913     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-007-0031-2     Document Type: Review

References (50)

1. Jemal A, Siegel R, Ward E, et al.: Cancer statistics 2007. CA Cancer J Clin 2007, 57:43-66.
2. Normanno N, Bianco C, De LA, et al.: Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer 2003, 10:1-21.
3. Janmaat ML, Giaccone G: The epidermal growth factor receptor pathway and its inhibition as anticancer therapy. Drugs Today (Barc) 2003, 39(Suppl C):61-80.
4. Baselga J: New technologies in EGFR-targeted cancer therapy. Signal 2000, 1:12-21.
5. Mendelsohn J, Baselga J: The EGF receptor family as targets for cancer therapy. Oncogene 2000, 19:6550-6565.
6. Salomon DS, Brandt R, Ciardiello F, Normanno N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995, 19:183-232.
7. Baselga J, Rischin D, Ranson M, et al.: Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002, 20:4292-4302.
8. Herbst RS, Maddox AM, Rothenberg ML, et al.: Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 2002, 20:3815-3825.
9. Ranson M, Hammond LA, Ferry D, et al.: ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002, 20:2240-2250.
10. Fukuoka M, Yano S, Giaccone G, et al.: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003, 21:2237-2246.
11. Kris MG, Natale RB, Herbst RS, et al.: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized Trial. JAMA 2003, 290:2149-2158.
12. Thatcher N, Chang A, Parikh P, et al.: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005, 366:1527-1537.
13. Hidalgo M, Siu LL, Nemunaitis J, et al.: Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001, 19:3267-3279.
14. Perez-Soler R, Chachoua A, Hammond LA, et al.: Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004, 22:3238-3247.
15. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al.: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
16. Lin WC, Chiu CH, Liou JL, et al.: Gefitinib as front-line treatment in Chinese patients with advanced non-small-cell lung cancer. Lung Cancer 2006, 54:193-199.
17. Suzuki R, Hasegawa Y, Baba K, et al.: A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer. Br J Cancer 2006, 94:1599-1603.
18. West HL, Franklin WA, McCoy J, et al.: Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. J Clin Oncol 2006, 24:1807-1813.
19. Giaccone G, Gallegos Ruiz M, Le Chevalier T, et al.: Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin Cancer Res 2006, 12:6049-6055.
20. Jackman DM, Yeap BY, Lindeman NI, et al.: Phase II clinical trial of chemotherapy-naive patients >= 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 2007, 25:751-753.
21. Gatzemeier U, Pluzanska A, Szczesna A, et al.: Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol 2004, 22:7010.
22. Giaccone G, Herbst RS, Manegold C, et al.: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004, 22:777-784.
23. Herbst RS, Giaccone G, Schiller JH, et al.: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a Phase III trial-INTACT 2. J Clin Oncol 2004, 22:785-794.
24. Herbst RS, Prager D, Hermann R, et al.: TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005, 23:5892-5899.
25. Herbst RS, Johnson DH, Mininberg E, et al.: Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005, 23:2544-2555.
26. Fan Z, Masui H, Altas I, Mendelsohn J: Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 1993, 53:4322-4328.
27. Hanna N, Lilenbaum R, Ansari R, et al.: Phase II Trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol 2006, 24:5253-5258.
28. Kim ES, Mauer AM, Tran HT, et al.: A phase II study of cetuximab, an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory / resistant patients with advanced non-small cell lung cancer: final report [abstract]. Proc ASCO 2003, 22:642.
29. Thienelt CD, Bunn PA Jr, Hanna N, et al.: Multicenter phase I/II study of cetuximab with paditaxel and carboplatin in Untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol 2005, 23:8786-8793.
30. Robert F, Blumenschein G, Herbst RS, et al.: Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. J Clin Oncol 2005, 23:9089-9096.
31. Rosell R, Daniel C, Ramlau R, et al.: Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC) [abstract]. J Clin Oncol Proc ASCO 2004, 22:7012.
32. Jensen AD, Munter MW, Bischoff H, et al.: Treatment of non-small cell lung cancer with intensity-modulated radiation therapy in combination with cetuximab: the NEAR protocol (NCT00115518). BMC Cancer 2006, 6:122.
33. Bonner JA, Harari PM, Giralt J, et al.: Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: A phase III study of high dose radiation therapy with or without cetuximab [abstract]. J Clin Oncol Proc ASCO 2004, 22:5507.
34. Shepherd FA, Dancey J, Ramlau R, et al.: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000, 18:2095-2103.
35. Hanna N, Shepherd FA, Fossella FV, et al.: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22:1589-1597.
36. Thomas L, Doyle LA, Edelman MJ: Lung cancer in women: emerging differences in epidemiology, biology, and therapy. Chest 2005, 128:370-381.
37. Tsao MS, Sakurada A, Cutz JC et al.: Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005, 353:133-144.
38. Wynder EL, Muscat JE: The changing epidemiology of smoking and lung cancer histology. Environ Health Perspect 1995, 103:(Suppl 8):143-148.
39. van Schaik RH: Cancer treatment and pharmacogenetics of cytochrome P450 enzymes. Invest New Drugs 2005, 23:513-522.
40. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al.: Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006, 24:5034-5042.
41. Paez JG, Janne PA, Lee JC et al.: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
42. Lynch TJ, Bell DW, Sordella R, et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
43. Pao W, Miller V, Zakowski M et al.: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004, 101:13306-13311.
44. Pao W and Miller VA: Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 2005, 23:2556-2568.
45. Bell DW, Lynch TJ, Haserlat SM, et al.: Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 2005, 23:8081-8092.
46. Hirsch FR, Varella-Garcia M, Bunn PA, Jr. et al.: Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003, 21:3798-3807.
47. Ferretti G, Felici A, Papaldo P, et al.: HER2/neu role in breast cancer: from a prognostic foe to a predictive friend. Curr Opin Obstet Gynecol 2007, 19:56-62.
48. Dziadziuszko R, Holm B, Skov BG, et al.: Epidermal growth factor receptor gene copy number and protein level are not associated with outcome of non-small-cell lung cancer patients treated with chemotherapy. Ann Oncol 2006 18:447-452.
49. Hirsch FR, Varella-Garcia M, McCoy J, et al.: Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol 2005, 23:6838-6845.
50. viel-Ronen S, Blackhall FH, Shepherd FA, Tsao MS: K-ras mutations in non-small-cell lung carcinoma: a review. Clin Lung Cancer 2006, 8:30-38.